

**AMENDMENTS TO THE CLAIMS
PURSUANT TO REVISED 37 CFR § 1.121**

The following is a listing of claims that replaces all prior versions, and listings, of claims in the application:

1. (Previously Presented) An aptamer-toxin conjugate therapeutic agent comprising a targeting moiety conjugated to a cytotoxic moiety wherein said targeting moiety is an aptamer specific for PSMA (Prostate Specific Membrane Antigen).
2. (Cancelled).
3. (Cancelled).
4. (Previously Presented) The therapeutic agent of claim 1 wherein said cytotoxic moiety is a small molecule chemotherapeutic agent.
5. (Withdrawn) The therapeutic agent of claim 3 wherein said cytotoxic moiety is selected from the group consisting of a cytotoxic peptide, a cytotoxic protein, a small molecule chemotherapeutic agent, and a radioisotope therapeutic molecule.
6. (Original) The therapeutic agent of claim 4, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.
7. (Withdrawn) The therapeutic agent of claim 5, wherein said targeting moiety is conjugated to said cytotoxic moiety by a covalent bond.
8. (Withdrawn) The therapeutic agent of claim 4 wherein said targeting moiety is conjugated to said cytotoxic moiety by a non-covalent bond.
9. (Withdrawn) The therapeutic agent of claim 5 wherein said targeting moiety is

conjugated to said cytotoxic moiety by a non-covalent bond.

10. (Currently Amended) An aptamer-~~drug~~ toxin conjugate comprising one or more aptamers, wherein at least one aptamer is specific for a PSMA (Prostate Specific Membrane Antigen), and a ~~drug~~ cytotoxic moiety linked by a linker and having the formula: (aptamer)_n -- linker -- (~~drug~~ cytotoxic moiety)_m, wherein n is between 1 and 10 and m is between 1 and 20.
11. (Cancelled).
12. (Withdrawn) The aptamer-drug conjugate of claim 10, wherein at least one of the one or more aptamers is specific for a target selected from the group consisting of PSMA, PSCA, e-selectin, an ephrin, ephB2, cripto-1, TENB2 (TEMFF2), ERBB2 receptor (HER2), MUC1, CD44v6, CD6, CD19, CD20, CD22, CD23, CD25, CD30, CD33, CD56, IL-2 receptor, HLA-DR10 β subunit, EGFRvIII, MN antigen, caveolin-1 and nucleolin the target PSMA.
13. (Currently Amended) The aptamer-~~drug~~ toxin conjugate of claim 10, wherein the ~~drug~~ cytotoxic moiety is a cytotoxin.
14. (Currently Amended) The aptamer-~~drug~~ toxin conjugate of claim 10, wherein the ~~drug~~ cytotoxic moiety is a vinca alkaloid.
15. (Currently Amended) The aptamer-~~drug~~ toxin conjugate of claim 10, wherein the ~~drug~~ cytotoxic moiety is desacetyl vinblastine 3-carboxhydrazide (DAVCH).
16. (Currently Amended) The aptamer-~~drug~~ toxin conjugate of claim 10, wherein the linker comprises one or more nucleophilic moieties, one or more electrophilic moieties or combinations thereof.
17. (Currently Amended) The aptamer-~~drug~~ toxin conjugate of claim 10, wherein the linker

is selected from the group consisting of a Boc-protected amine, a Boc-protected amine on a heterobifunctional linker, a nucleophilic dendrimer, an electrophilic dendrimer and an electrophilic comb polymer.

18. (Currently Amended) The aptamer-~~drug~~ toxin conjugate of claim 10, wherein the linker is selected from the group consisting of Boc-NH₂-PEG-NHS, an erythritol dendrimer, an octa-polyethylene glycol dendrimer and comb polymer.